𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Pegylated interferon–induced immune-mediated hepatitis post–liver transplantation

✍ Scribed by Nickolas Kontorinis; Kaushik Agarwal; Nassim Elhajj; M. Isabel Fiel; Thomas D. Schiano

Publisher
John Wiley and Sons
Year
2006
Tongue
English
Weight
261 KB
Volume
12
Category
Article
ISSN
1527-6465

No coin nor oath required. For personal study only.

✦ Synopsis

A 55-year-old Caucasian male developed a well characterized autoimmune hepatitis after completing treatment with pegylated interferon and ribavirin for recurrent hepatitis C. We hypothesize that pegylated interferon triggered a severe form of immune-mediated hepatitis.

📜 SIMILAR VOLUMES

Treatment of chronic hepatitis E in live
Treatment of chronic hepatitis E in liver transplant recipients with pegylated interferon alpha-2b
✍ Elizabeth B. Haagsma; Annelies Riezebos-Brilman; Arie P. van den Berg; Robert J. 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 170 KB 👁 1 views

Hepatitis E virus (HEV) infections are known to run a self-limiting course. Recently, chronic hepatitis E has been described in immunosuppressed patients after solid-organ transplantation. Besides the general recommendation to lower the immunosuppressive medication in these patients, there is curren

Clinical and histological efficacy of pe
Clinical and histological efficacy of pegylated interferon and ribavirin therapy of recurrent hepatitis C after liver transplantation
✍ Inmaculada Fernández; Juan Carlos Meneu; Francisco Colina; Ignacio García; Raque 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 143 KB 👁 2 views

Treatment of recurrent hepatitis C in liver transplant is controversial. The aim of our study was to evaluate the clinical and histological efficacy of pegylated interferon alpha 2b (PEG-IFN) and ribavirin therapy of recurrent hepatitis C after liver transplantation (LT). We prospectively included 4

Anemia is not predictive of sustained vi
Anemia is not predictive of sustained virological response in liver transplant recipients with hepatitis C virus who are treated with pegylated interferon and ribavirin
✍ Michela Giusto; Maria Rodriguez; Laia Navarro; Angel Rubin; Victoria Aguilera; F 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 148 KB 👁 1 views

In the immunocompetent setting, antiviral therapy-related anemia has recently been shown to be associated with a sustained virological response (SVR). Our goal was to assess whether this is also true for liver transplantation (LT). We included 160 LT patients with recurrent hepatitis C virus (HCV) w

Protective antibody levels and dose requ
Protective antibody levels and dose requirements for IV 5% Nabi Hepatitis B immune globulin combined with lamivudine in liver transplantation for hepatitis B-induced end stage liver disease
✍ Rolland C. Dickson; Norah A. Terrault; Michael Ishitani; K. Rajender Reddy; Patr 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 185 KB 👁 1 views

Lamivudine combined with Hepatitis B immune globulin (HBIg) prevents post liver transplant (LT) HBV recurrence. The study was designed to assess the impact of lamivudine on hepatitis B antibody (anti-HBs) and dosage requirements of intravenous 5% HBIg (Nabi-HB) in the first 36 weeks post LT. Adults

Prediction of sustained virological resp
Prediction of sustained virological response in liver transplant recipients with recurrent hepatitis C virus following combination pegylated interferon alfa-2b and ribavirin therapy using tissue hepatitis C virus reverse transcriptase polymerase chain reaction testing
✍ Guy W. Neff; Christopher B. O'Brien; Robert Cirocco; Marzia Montalbano; Maria de 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 69 KB 👁 2 views

The optimal duration of therapy for pegylated interferon combined with ribavirin in recurrent Hepatitis C virus (HCV) following liver transplantation is not known. We wanted to determine if testing for HCV in liver tissue by reverse transcriptase polymerase chain reaction (RT-PCR) was superior in pr